Molecular Therapeutics®

  “Innovations In Microbial Control”                          

 

Copyright 2015. All Rights Reserved

Broad spectrum in vitro antimicrobial activity even against drug resistant microbes such as Methicillin resistant Staphylococcus aureus (MRSA), Vancomycin resistant Enterococcus faecalis (VRE), multi-drug resistant Pseudomonas aeruginosa, and multi-drug resistant Acinetobacter baumannii

Indications for  SilvaKlenz® and Silvion® include:                         ORDER NOW------

1st and 2nd Degree Burns, Stage I-IV Pressure Ulcers, Venous Stasis Ulcers,

Diabetic Ulcers, Post Surgical Wounds, Dermal Lesions, Skin Irritation, Abrasions Does Not Contain Alcohol, Triclosan nor Benzoyl Chloride. FDA Clearance.


All Clinical Cases - 2nd Degree Burn Cases - Cold Sore Case - Shingles Case - Post Radiation Burn Cases - Post Surgical Cases - Post Mastectomy Wound Cases - Stage IV Ulcers Cases

Molecular Therapeutics, Silvion, SilvaKlenz, Potentiator and Potentiated are registered trademarks.

Molecular Therapeutics, LLC  111 Riverbend Rd, Suite 264 Athens, GA 30602 Contact Us

Numerous reports in the media and professional medical literature have expressed grave concerns about the effectiveness of currently available antibiotics against multi-drug resistant bacteria. Some strains of pathogenic bacteria have demonstrated rapidly evolving defense strategies that render antibiotics worthless. One defense strategy used by microbes is to secrete a substance known as biofilm, which provides a protective shield effectively blocking antimicrobials from contacting the microbe.

Professional use only

SilvaKlenz® and Silvion® were one of 23 technologies featured in the 2011 Better World Report, published by the Association of University Technology Managers. The Better World Report, published annually, promotes public understanding of how academic research and technology transfer have changes people's way of life and made the world a better place.

SilvaKlenz® and Silvion® are the  first two products incorporating this revolutionary     Potentiated® antimicrobial technology to receive FDA clearance for professional use. These solutions have been proven to kill todays most pathogenic bacteria including multiple-drug-resistant bacteria such as Methicillin-resistant Staphylococcus aureus, Acinetobacter baumannii, and Enterococcus faecalis.


In vitro testing has shown that microbes that quickly develop resistance to antimicrobials in vivo, are unlikely to remain resistant or develop resistance to Potentiated® antimicrobials.

An innovative technology, based upon research conducted by the Emerging Disease Research Group at the University Of Georgia, has been developed that significantly enhances and potentiates the killing activity of topical antimicrobials. This new class of antimicrobials destroys protective biofilms as well as the integrity and functionality of the microbe’s cellular membrane.

The following electron micrographs demonstrate the effect of Potentiated® antimicrobials, against a multi-drug resistant Pseudomonas aeruginosa.

Normal “Intact” cell Membrane Before Treatment

Potentiator®    induced Cytoplasmic Leakage Facilitating Bacteria Death